支气管哮喘遇上β-受体阻滞剂  

Bronchial asthma meets β-blocker

作　　者：顾婷婷 姚莉[2] GU Tingting;YAO Li(Department of Pharmacy,Hami Central Hospital,Xinjiang Hami 839000,China;Department of Pharmacy,Traditional Chinese Medicine Hospital affiliated to Xinjiang Medical University,Urumchi 830000,China)

机构地区：[1]新疆哈密市中心医院药剂科,新疆哈密839000 [2]新疆医科大学附属中医医院药学部,乌鲁木齐830000

出　　处：《上海医药》2019年第21期62-65,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:探讨β-受体阻滞剂在心律失常合并哮喘患者中的应用。方法:临床药师参与1例在治疗过程中使用β-受体阻滞剂的心律失常合并哮喘患者的用药方案的制订与用药监护。结果:对于呼吸道风险高于心血管获益的患者,可以选用伊伐布雷定或非二氢吡啶类钙通道阻滞剂地尔硫?作为其替代治疗药物。结论:临床药师应运用临床及药学知识,帮助医师制订个体化用药方案,以体现工作价值。Objective:To explore the application of β-blocker in patients with arrhythmia and asthma.Methods:Clinical pharmacists were involved in the development of medication regimen and medication monitoring of a patient using betablocker for the treatment of arrhythmia and asthma.Results:For patients whose respiratory risk is higher than cardiovascular benefit,ivabradine or diltiazem,a non-dihydropyridine calcium channel blocker,may be used as an alternative treatment.Conclusion:Clinical pharmacists are expected to apply their clinical and pharmaceutical knowledge to assist the physicians in developing individualized medication regimens so as to realize their professional value.

关 键 词：Β-受体阻滞剂 心律失常 哮喘 伊伐布雷定 

分 类 号：R562.25[医药卫生—呼吸系统] R969.3[医药卫生—内科学]